|
|
Article: Study Demonstrates Long-Term Use of Eszopiclone for Treatment of Insomnia; Study Showed Improvements in Sleep and Daytime Function For Chronic Insomnia Patients.
- Article from:
- PR Newswire
- Article date:
- May 6, 2004
|
Copyright informationCOPYRIGHT 2004 PR Newswire Association, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW YORK, May 6 /PRNewswire/ -- Results from a year-long study of eszopiclone, a non-benzodiazepine under development by Sepracor Inc. for the treatment of insomnia, were presented today at the 157th annual meeting of the American Psychiatric Association. In the study, eszopiclone provided sustained improvement in sleep and daytime function over 12 months of treatment. Additionally, patients previously treated with placebo during the first six months of the study reported an immediate and significant improvement in sleep and daytime functioning upon receiving eszopiclone.
"Eszopiclone demonstrated significant long-term improvements for all measures of insomnia, including ...
Related newspaper, magazine, and journal articles:
|
|
Article: Solicitation or harassment?
Tribune-Review/Pittsburgh Tribune-Review;
September 17, 2007 ;
700+ words
......keep their legs in motion," explains NINDS, "especially when sitting," as on a toilet. Side effects include "impairment of daytime function." An estimated six million guys have RLS, "often underdiagnosed," a disorder "more common with increasing age." There's...
|
|